Overview

A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
This proof-of-concept trial is being conducted to evaluate the efficacy, safety and tolerability of combination treatment with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 11 years.
Phase:
PHASE2
Details
Lead Sponsor:
Ascendis Pharma Growth Disorders A/S